Aducanumab

Alternative Names: Aduhelm

Aducanumab s an anti-amyloid antibody approved by the FDA in 2021 for Alzheimer’s disease under accelerated approval, based on its ability to reduce brain amyloid plaques. Its approval is controversial because trials showed mixed evidence of clinical benefit, with only modest slowing of decline in some analyses. The drug carries risks of amyloid-related imaging abnormalities (ARIA), requiring regular MRI monitoring. Due to uncertain benefit and safety concerns, its use is very limited and mostly restricted to clinical trial settings.

Treatment Type: Prescription Medication

Treatment Class: Monoclonal antibody

Treatment Modality: Intravenous (IV)

Aducanumab

Review Summary

3.0

1 Reviews

Preferred by 0 Reviewers

Based on the provided review, Aducanumab shows uncertain clinical effectiveness for Alzheimer's disease despite its ability to reduce amyloid plaques. The treatment remains controversial due to safety concerns and limited evidence, and is currently reserved only for carefully selected patients, primarily in clinical trial settings.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
0
1 = Very Expensive 5 = Very Affordable

0

Very Expensive
Relief Speed
0
1 = No Relief 5 = Immediate Relief

0

No Relief
Side Effects
0
1 = Intolerable Effect 5 = No Effect

0

Intolerable Effect
Treatment Line
0
1 = Third-line or more 5 = First-line

0

Third-line or more

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

3.0

1 Reviews
5
0%
4
0%
3
100%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the provided review, Aducanumab shows uncertain clinical effectiveness for Alzheimer's disease despite its ability to reduce amyloid plaques. The treatment remains controversial due to safety concerns and limited evidence, and is currently reserved only for carefully selected patients, primarily in clinical trial settings.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
9 months ago
Aducanumab's FDA approval remains highly controversial due to uncertain clinical benefit despite reducing amyloid plaques. Because of safety concerns and limited evidence, it is reserved for very select patients and is generally available only in the context of a clinical trial setting.
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All